A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused ...

Several tumor features were linked with a higher chance of pCR: no or low ER levels, low or no progesterone receptor levels, ...

For children with high-risk B-cell acute lymphoblastic leukemia (ALL), replacing part of their intensive chemotherapy with ...

Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo ...

Living with incurable small lymphocytic lymphoma means facing new health challenges and fears while finding a balance between ...

The trial met its primary end point of progression-free survival in patients with an International Prognostic Index (IPI) ...

Ameluz photodynamic therapy is the first light-based treatment the FDA has approved for a skin cancer. Here's who it's for, ...

Katie Parrinello was diagnosed with primary mediastinal B-cell lymphoma at 29, reached remission four days before turning 30 ...

Breast cancer survivor Sue Weldon discusses survivorship gaps, integrative therapies alongside treatment and why caregivers ...

Mechanistically, 18F-FET uptake reflects heightened LAT1/LAT2 amino-acid transport in tumor, typically yielding higher ...

With a traditional nipple-sparing mastectomy, the surgeon typically makes a relatively large incision along the lower part of the breast, sometimes measuring 9 to 10 centimeters. The skin and nipple ...

DeLLphi-305 randomized 563 nonprogressing ES-SCLC patients post induction durvalumab plus platinum/etoposide to durvalumab maintenance with or without tarlatamab, with overall survival as the primary ...